Media stories about ImmunoGen (NASDAQ:IMGN) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm scores the sentiment of press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. ImmunoGen earned a media sentiment score of 0.16 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 47.3990721675183 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
These are some of the media stories that may have impacted Accern Sentiment’s scoring:
- ImmunoGen (IMGN) Reports Wider-than-Expected Q3 Loss – Nasdaq (nasdaq.com)
- ImmunoGen, Inc. (IMGN) could lose another bull – Argus Journal – Argus Journal (argusjournal.com)
- Edited Transcript of IMGN earnings conference call or presentation 3-Nov-17 12:00pm GMT (finance.yahoo.com)
- ImmunoGen, Inc. (IMGN) Posts Quarterly Earnings Results, Misses Expectations By $0.42 EPS (americanbankingnews.com)
- Immunogen (IMGN) to Present New Data on Novel Antibody-Drug Conjugates at ASH (streetinsider.com)
Several brokerages have recently weighed in on IMGN. Zacks Investment Research cut ImmunoGen from a “hold” rating to a “sell” rating in a research report on Monday, July 10th. Canaccord Genuity reiterated a “buy” rating and issued a $10.00 price target (up from $8.00) on shares of ImmunoGen in a research report on Wednesday, August 30th. Cowen and Company reiterated a “hold” rating on shares of ImmunoGen in a research report on Tuesday, August 29th. Cantor Fitzgerald set a $5.00 price objective on ImmunoGen and gave the company a “hold” rating in a research note on Friday, July 28th. Finally, Jefferies Group LLC reissued a “buy” rating and set a $9.00 price objective on shares of ImmunoGen in a research note on Thursday, October 12th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $7.83.
ImmunoGen (NASDAQ:IMGN) traded up $0.32 during trading hours on Friday, reaching $5.63. The company had a trading volume of 6,970,746 shares, compared to its average volume of 4,062,375. ImmunoGen has a 12 month low of $1.53 and a 12 month high of $8.84. The company has a debt-to-equity ratio of -0.56, a current ratio of 2.40 and a quick ratio of 2.34.
ImmunoGen (NASDAQ:IMGN) last posted its quarterly earnings data on Friday, November 3rd. The biotechnology company reported ($0.61) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by ($0.42). The company had revenue of $8.50 million during the quarter, compared to the consensus estimate of $26.09 million. The business’s revenue for the quarter was up 10.4% compared to the same quarter last year. During the same period last year, the company earned ($0.51) earnings per share. equities research analysts anticipate that ImmunoGen will post -0.82 EPS for the current year.
In related news, VP Craig Barrows sold 37,050 shares of ImmunoGen stock in a transaction on Friday, September 15th. The stock was sold at an average price of $6.81, for a total transaction of $252,310.50. Following the completion of the sale, the vice president now owns 51,100 shares of the company’s stock, valued at $347,991. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 6.51% of the stock is currently owned by company insiders.
TRADEMARK VIOLATION NOTICE: “Somewhat Favorable Media Coverage Somewhat Unlikely to Impact ImmunoGen (IMGN) Stock Price” was posted by Community Financial News and is the property of of Community Financial News. If you are reading this report on another site, it was stolen and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://www.com-unik.info/2017/11/05/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-immunogen-imgn-stock-price.html.
ImmunoGen Company Profile
ImmunoGen, Inc is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target.
What are top analysts saying about ImmunoGen Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for ImmunoGen Inc. and related companies.